Embedded Files
Advertise with Aurax News — Reach a Global Audience Today.
FDA Commissioner Marty Makary Resigns Amid Agency Upheaval
By Aurax Desk | May 13, 2026 | 2 min read
Food and Drug Administration Commissioner Marty Makary is stepping down after a brief tenure marked by political pressure and internal uncertainty at the federal health agency. His departure comes as the FDA faces scrutiny over vaccine policy, staffing changes and leadership stability under President Donald Trump’s administration.
The FDA is facing renewed scrutiny following the resignation of Commissioner Marty Makary.
The commissioner of the U.S. Food and Drug Administration plans to resign, according to multiple media reports published Monday, ending a short and turbulent period leading one of the nation’s most influential health agencies.
Marty Makary, a surgeon and public health researcher who assumed the role earlier this year, oversaw the FDA during a period of heightened political attention surrounding vaccines, drug approvals and federal public health policy. His resignation comes amid broader changes across U.S. health agencies and follows reports of internal disagreements over regulatory direction and staffing decisions.
The FDA has been navigating increased scrutiny from lawmakers, medical groups and public health advocates over its handling of vaccine recommendations and pharmaceutical oversight. Recent debates surrounding vaccine policy, including questions about authorization processes and communication with the public, intensified pressure on agency leadership.
Marty Makary served as FDA commissioner during a period of debate over vaccine policy and agency reforms.
Makary’s tenure also unfolded during a period of restructuring within federal health institutions led by Health and Human Services Secretary Robert F. Kennedy Jr., whose positions on vaccines and regulatory reform have generated national debate. The administration has pursued changes aimed at reshaping federal health agencies, including reviews of scientific advisory panels and staffing levels.
Reports indicated that tensions within the FDA had grown in recent weeks as employees and outside experts raised concerns about uncertainty surrounding agency priorities and decision-making. Public health analysts have warned that leadership turnover at the FDA could affect confidence in regulatory processes tied to medicines, vaccines and food safety oversight.
The White House and the Department of Health and Human Services had not immediately announced a successor. The FDA commissioner role requires Senate confirmation, and any leadership transition is expected to draw close attention from lawmakers and healthcare organizations.
The FDA plays a central role in regulating prescription drugs, vaccines, medical devices and food products in the United States. Changes in leadership at the agency often carry significant implications for pharmaceutical companies, healthcare providers and public health policy nationwide.
Sources: Information sourced from the Associated Press, Reuters, The Washington Post and BBC News.
Page updated
Google Sites
Report abuse